Idorsia Pharmaceutical. has filed a patent for novel crystalline forms of {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide, their preparation processes, pharmaceutical compositions, and use as endothelin receptor antagonists. The patent also covers new uses of the compound alone or in combination with other therapeutic agents. GlobalData’s report on Idorsia Pharmaceutical gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Idorsia Pharmaceutical Ltd - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Idorsia Pharmaceutical, Cancer treatment biomarkers was a key innovation area identified from patents. Idorsia Pharmaceutical's grant share as of January 2024 was 52%. Grant share is based on the ratio of number of grants to total number of patents.

Novel crystalline forms of endothelin receptor antagonist

Source: United States Patent and Trademark Office (USPTO). Credit: Idorsia Pharmaceutical Ltd

A pharmaceutical patent application (Publication Number: US20230391757A1) describes a novel pharmaceutical unit dosage form for oral administration. The dosage form includes a crystalline form of {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide. This solid dosage form contains specific ingredients in defined amounts, such as microcrystalline cellulose, lactose, hydroxypropylcellulose, croscarmellose sodium, and magnesium stearate. The crystalline form of the active ingredient is characterized by specific peaks in the X-ray powder diffraction diagram, indicating its unique structure.

Furthermore, the patent application details the process for preparing this pharmaceutical composition, involving mixing the crystalline form of the active ingredient with the specified excipients. The dosage form is designed to deliver 10 to 50 mg per day of {5-(4-bromo-phenyl)-6-[2-(5-bromo-pyrimidin-2-yloxy)-ethoxy]-pyrimidin-4-yl}-sulfamide. The X-ray powder diffraction diagram of the crystalline form is crucial for confirming its identity and purity, with specific peaks at defined angles of refraction. This innovative dosage form, presented as a tablet, offers a precise and effective way of administering the active ingredient for potential therapeutic applications.

To know more about GlobalData’s detailed insights on Idorsia Pharmaceutical, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies